Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SBS003
MIFTS: 54

Substance Abuse

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Substance Abuse

About this section

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 15
Substance-Related Disorders 44 70
Substance Abuse Problem 70

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:302
MeSH 44 D019966
NCIt 50 C16522
SNOMED-CT 67 26416006
UMLS 70 C0013146 C0236969 C0740858
Sources

Summaries for Substance Abuse

About this section
Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to depression and alcohol use disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Lidocaine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and heart, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 73 Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods which are... more...

Sources

Related Diseases for Substance Abuse

About this section

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 depression 32.5 SLC6A4 PRL MAOA BDNF
2 alcohol use disorder 32.5 SLC6A4 SLC6A3 HTR1B GABRA2 DRD3 DRD2
3 cannabis abuse 32.4 GABRA2 DRD4 DRD2 COMT BDNF
4 opioid abuse 32.4 SLC6A3 DRD2 CYP2D6
5 amphetamine abuse 32.4 SLC6A4 SLC6A3 HTR1B
6 schizoaffective disorder 32.3 SLC6A4 PRL DRD3 DRD2 COMT BDNF
7 eating disorder 32.3 SLC6A4 SLC6A3 NPY DRD3 DRD2 COMT
8 borderline personality disorder 32.2 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD2
9 cocaine abuse 32.2 SLC6A4 SLC6A3 PRL MOBP DRD2 DBH
10 bipolar disorder 32.0 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
11 post-traumatic stress disorder 31.9 SLC6A4 MAOA DRD2 DBH COMT BDNF
12 drug dependence 31.7 SLC6A4 SLC6A3 GABRA2 DRD3 DRD2 BDNF
13 alcohol dependence 31.7 SLC6A4 SLC6A3 NPY MAOA HTR1B GABRA2
14 personality disorder 31.6 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD4
15 traumatic brain injury 31.6 DRD2 COMT BDNF
16 schizophrenia 31.5 SLC6A4 SLC6A3 PRL NPY MOBP MIAT
17 opiate dependence 31.5 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
18 brain injury 31.5 DRD2 COMT BDNF
19 substance dependence 31.5 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
20 conduct disorder 31.4 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
21 polysubstance abuse 31.4 DRD3 DRD2 COMT
22 mental depression 31.3 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD2
23 mood disorder 31.3 SLC6A4 SLC6A3 NPY MAOA HTR1B DRD4
24 antisocial personality disorder 31.3 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
25 tobacco addiction 31.2 SLC6A4 SLC6A3 MAOA GABRA2 DRD4 DRD3
26 cocaine dependence 31.2 SLC6A4 SLC6A3 NPY GABRA2 DRD3 DRD2
27 psychotic disorder 31.1 SLC6A4 SLC6A3 PRL MAOA DRD4 DRD3
28 attention deficit-hyperactivity disorder 31.1 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
29 anorexia nervosa 31.1 SLC6A4 PRL NPY MAOA DRD4 COMT
30 adjustment disorder 31.0 SLC6A4 NPY CYP2D6 BDNF
31 anxiety 31.0 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
32 disease of mental health 31.0 SLC6A4 SLC6A3 PRL NPY MOBP MAOA
33 bipolar i disorder 31.0 SLC6A4 DRD2 COMT BDNF
34 pathological gambling 31.0 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
35 generalized anxiety disorder 31.0 SLC6A4 SLC6A3 NPY MAOA DRD2 CYP2D6
36 social phobia 30.9 SLC6A4 PRL MAOA DRD2 COMT BDNF
37 bulimia nervosa 30.9 SLC6A4 NPY MAOA HTR1B DRD4 DRD2
38 major depressive disorder 30.9 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
39 panic disorder 30.8 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
40 neurotic disorder 30.8 SLC6A4 MAOA COMT BDNF
41 alexithymia 30.8 SLC6A4 DRD2 COMT
42 dysthymic disorder 30.8 SLC6A4 SLC6A3 MAOA DRD4 COMT BDNF
43 dementia 30.8 SLC6A3 DRD2 COMT BDNF BCHE
44 agoraphobia 30.8 SLC6A4 MAOA COMT
45 movement disease 30.8 SLC6A3 DRD3 DRD2 CYP2D6 COMT BDNF
46 tardive dyskinesia 30.8 DRD4 DRD3 DRD2 CYP2D6 COMT
47 sleep disorder 30.8 SLC6A4 SLC6A3 PRL NPY COMT BDNF
48 schizophreniform disorder 30.7 SLC6A3 PRL DRD2 COMT BDNF
49 somatization disorder 30.7 SLC6A4 COMT
50 sexual disorder 30.7 SLC6A4 PRL CYP2D6 BDNF

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse
Sources

Symptoms & Phenotypes for Substance Abuse

About this section

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 BDNF COMT CYBB DBH DRD2 DRD3
2 cardiovascular system MP:0005385 9.96 COMT CYBB DBH DRD2 DRD3 DRD5
3 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DBH DRD2 DRD5 HTR1B
4 homeostasis/metabolism MP:0005376 9.8 BCHE BDNF COMT CYBB DBH DRD2
5 nervous system MP:0003631 9.5 BDNF COMT CYBB DBH DRD2 DRD3
Sources

Drugs & Therapeutics for Substance Abuse

About this section

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Desipramine Approved, Investigational Phase 4 50-47-5 2995
7
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
8
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
9
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
10
Amantadine Approved Phase 4 768-94-5 2130
11
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
12
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
13
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
14
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
15
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
16
sodium fluoride Approved Phase 4 7681-49-4
17
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
18
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
21
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
22
Methadone Approved Phase 4 76-99-3 4095
23
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
24
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
25
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Clozapine Approved Phase 4 5786-21-0 2818
28
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
29
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
30
Choline Approved, Nutraceutical Phase 4 62-49-7 305
31
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
32
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
33
Raclopride Investigational Phase 4 84225-95-6
34
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
35
Lecithin Experimental Phase 4 8002-43-5
36 Antimetabolites Phase 4
37 Antiparkinson Agents Phase 4
38 Liver Extracts Phase 4
39 Serotonin 5-HT1 Receptor Agonists Phase 4
40 Dopamine Antagonists Phase 4
41 interferons Phase 4
42 Cytochrome P-450 Enzyme Inhibitors Phase 4
43 Nootropic Agents Phase 4
44 Antidepressive Agents, Tricyclic Phase 4
45 Sodium Channel Blockers Phase 4
46 Diuretics, Potassium Sparing Phase 4
47 Reverse Transcriptase Inhibitors Phase 4
48 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
49 Anti-HIV Agents Phase 4
50 Vasoconstrictor Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1428)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Unknown status NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
3 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
6 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
7 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
8 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
9 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
10 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
11 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
12 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
13 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
14 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
15 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
16 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
17 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
18 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
19 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
20 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
21 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
22 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
23 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
24 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
25 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
26 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
27 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Completed NCT03842436 Phase 4 Truvada
28 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
29 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
30 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
31 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
32 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
33 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
34 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
35 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
36 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
37 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
38 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
39 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
40 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
41 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
42 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
43 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
44 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
45 Smoking Cessation Treatment for Methadone Maintenance Patients Completed NCT01027754 Phase 4 Varenicline;Placebo
46 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
47 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
48 An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADEâ„¢) Completed NCT04060654 Phase 4 Sublocade
49 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
50 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Desipramine
Desipramine Hydrochloride
Doxapram
Doxapram Hydrochloride

Cochrane evidence based reviews: substance-related disorders

Sources

Genetic Tests for Substance Abuse

About this section

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29
Sources

Anatomical Context for Substance Abuse

About this section

MalaCards organs/tissues related to Substance Abuse:

40
Brain, Cortex, Heart, Spinal Cord, Kidney, Prefrontal Cortex, Liver
Sources

Publications for Substance Abuse

About this section

Articles related to Substance Abuse:

(show top 50) (show all 24774)
# Title Authors PMID Year
1
Polysubstance abuse among sexually abused in alcohol, drug, and gambling addiction treatment in Greenland: a cross sectional study. 61
33250010 2021
2
Top-down and bottom-up attentional biases for smoking-related stimuli: Comparing dependent and non-dependent smokers. 61
33714035 2021
3
Coping strategies in obsessive-compulsive patients during Covid-19 lockdown. 61
33519939 2021
4
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. 61
33771282 2021
5
Assessing Community Needs to Combat the Opioid Epidemic in Washtenaw County, Michigan. 61
33785692 2021
6
ADHD Is Associated With a Widespread Pattern of Risky Behavior Across Activity Domains. 61
31583930 2021
7
Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications. 61
33587920 2021
8
25 Years of the International Bipolar Collaborative Network (BCN). 61
33811284 2021
9
Availability of Outpatient Telemental Health Services in the United States at the Outset of the COVID-19 Pandemic. 61
33480660 2021
10
Borderline Personality Disorder Features and Risk for Prescription Opioid Misuse in a Chronic Pain Sample: Roles for Identity Disturbances and Impulsivity. 61
31609188 2021
11
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors. 61
33764950 2021
12
Prevalence and characteristics of starvation-related malnutrition in a mid-atlantic healthcare system: a cohort study. 61
33811347 2021
13
Evaluation of dexmedetomidine withdrawal in critically ill adults. 61
33227592 2021
14
Increased availability of telehealth mental health and substance abuse treatment for peripartum and postpartum women: A unique opportunity to increase telehealth treatment. 61
33612199 2021
15
Systematic Suicide Audit: An Enhanced Method to Assess System Gaps and Mobilize Leaders for Prevention. 61
33633004 2021
16
Perinatal suicidality: prevalence and correlates in a South African birth cohort. 61
33792768 2021
17
CBT and CFT for Chronic Pain. 61
33791876 2021
18
Health Care Utilization Due to Substance Abuse Among Homeless and Nonhomeless Children and Young Adults in New York. 61
33789461 2021
19
Latina and Caribbean Immigrant Women's Experiences With Intimate Partner Violence: A Story of Ambivalent Sexism. 61
29860910 2021
20
The Effect of Sex and Perpetrator-Victim Relationship on Perceptions of Domestic Homicide. 61
29768992 2021
21
Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(-)-ketamine. 61
33577868 2021
22
American Association for Emergency Psychiatry Recommendations to Address Psychiatric Staff Shortages in Emergency Settings. 61
33467869 2021
23
Engaging Community Networks to Improve Depression Services: A Cluster-Randomized Trial of a Community Engagement and Planning Intervention. 61
32430557 2021
24
Stigma in the News: The Representation and Trivialization of Stigma in U.S. News Publications. 61
31739679 2021
25
Why We Come: Clubhouse Members Seek Connection, Purpose and Meaning. 61
32671506 2021
26
Does increasing health care access reduce disability insurance caseloads? Evidence from the rural United States. 61
33476081 2021
27
Health Care Utilization of Individuals Affected by Homelessness: Illinois, 2011-2018. 61
33710089 2021
28
A Latent Class Analysis of Prevention Approaches Used to Reduce Community-Level Prescription Drug Misuse in Adolescents and Young Adults. 61
33811569 2021
29
Utility of the READMIT Index to Identify Community Hospital 30-Day Psychiatric Readmissions. 61
33027602 2021
30
Promising vulnerability markers of substance use and misuse: A review of human neurobehavioral studies. 61
33607147 2021
31
Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight. 61
33597276 2021
32
A sibling's narrative of recovery from addiction trauma and loss in the family. 61
32598536 2021
33
Commentary: Substance use and the brain: it is not straightforward to differentiate cause from consequence - a commentary on Kim-Spoon et al. (2020). 61
32803755 2021
34
Incidence and characteristics of spinal injuries in the victims of intimate partner violence (IPV). 61
33000362 2021
35
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. 61
33612201 2021
36
Substance use among patients in specialized mental health services in Norway: prevalence and patient characteristics based on a national census. 61
32945698 2021
37
Blockade of alcohol excessive and "relapse" drinking in male mice by pharmacological cryptochrome (CRY) activation. 61
33420591 2021
38
Sex differences in progestogen- and androgen-derived neurosteroids in vulnerability to alcohol and stress-related disorders. 61
33600842 2021
39
Explaining Service Use and Residential Stability in Supported Housing: Problems, Preferences, Peers. 61
33710083 2021
40
Cognitive function in patients prior to undergoing allogeneic hematopoietic stem cell transplantation. 61
32829465 2021
41
Substance Use in a Domestic Minor Sex Trafficking Patient Population. 61
30870343 2021
42
Outcomes of an interprofessional SBIRT training program: Knowledge attainment and perceived competence for practice. 61
33797345 2021
43
Pathogenic paternally inherited NLGN4X deletion in a female with autism spectrum disorder: Clinical, cytogenetic, and molecular characterization. 61
33369065 2021
44
Cannabis use and hippocampal subfield volumes in males with a first episode of a schizophrenia spectrum disorder and healthy controls. 61
33740561 2021
45
The Influence of Substance Abuse on Inhibition Capacities and Risky Decision in a Group of Outpatient Schizophrenia Patients. 61
33784943 2021
46
Vocational Outcomes of the Individual Placement and Support Model in Subgroups of Diagnoses, Substance Abuse, and Forensic Conditions: A Systematic Review and Analysis of Pooled Original Data. 61
33661452 2021
47
Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review. 61
33706723 2021
48
National rates and trends of tobacco and substance use disorders among atrial fibrillation hospitalizations. 61
33359929 2021
49
A nationwide analysis of maternal morbidity and acute postpartum readmissions in women with epilepsy. 61
33706248 2021
50
Prior Exposure to Intimate Partner Violence Associated With Less HIV Testing Among Young Women. 61
29651922 2021
Sources

Variations for Substance Abuse

About this section
Sources

Expression for Substance Abuse

About this section
Search GEO for disease gene expression data for Substance Abuse.
Sources

Pathways for Substance Abuse

About this section

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.48 PRL NPY HTR1B GABRA2 DRD5 DRD4
2
Transmission across Chemical Synapses 65
Show member pathways
 12.87 SLC6A4 SLC6A3 MAOA GABRA2 COMT BCHE
3
Beta-Adrenergic Signaling 63
Show member pathways
 12.68 DRD5 DRD4 DRD3 DRD2 BDNF
4
Circadian entrainment 36
Show member pathways
 12.58 SLC6A3 MAOA DRD5 DRD4 DRD3 DRD2
5
Dopamine-DARPP32 Feedback onto cAMP Pathway 63
12.23 DRD5 DRD4 DRD3 DRD2
7
cAMP signaling pathway 36
12.17 NPY HTR1B DRD5 DRD2 BDNF
8
Amphetamine addiction 36
Show member pathways
 11.88 SLC6A3 MAOA DRD2 BDNF
9
Imipramine/Desipramine Pathway, Pharmacokinetics 60
Show member pathways
 11.84 SLC6A4 CYP2D6 CYP2C19 COMT
10
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.79 DRD4 DRD3 DRD2
11
Serotonergic synapse 36
11.72 SLC6A4 MAOA HTR1B CYP2D6 CYP2C19
12
Phenylalanine metabolism 36
Show member pathways
 11.67 MAOA DBH COMT
13
Monoamine GPCRs 1
Show member pathways
 11.6 HTR1B DRD5 DRD4 DRD3 DRD2
14
Phenytoin Pathway, Pharmacokinetics 60
Show member pathways
 11.53 CYP2D6 CYP2C19 COMT
15
Melatonin metabolism and effects 1
11.27 MAOA CYP2D6 CYP2C19
16
Monoamine Transport 1
Show member pathways
 11.26 SLC6A4 SLC6A3 MAOA DBH
17
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
11.1 SLC6A4 MAOA HTR1B
18
Biogenic Amine Synthesis 1
Show member pathways
 10.98 MAOA DBH COMT
19
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.88 PRL NPY DRD2
20
noradrenaline and adrenaline degradation 1
Show member pathways
 10.8 MAOA COMT
21
Bupropion Pathway, Pharmacokinetics 60
10.79 CYP2D6 CYP2C19
22
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 10.77 SLC6A4 SLC6A3 MAOA COMT BCHE
23
Dopamine metabolism 1
10.75 MAOA COMT
24
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.68 SLC6A4 SLC6A3 MAOA HTR1B DRD5 DRD4
25
Propranolol Pathway, Pharmacokinetics 60
10.52 MAOA CYP2D6
Sources

GO Terms for Substance Abuse

About this section

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.29 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
2 synapse GO:0045202 9.87 SLC6A4 NPY GABRA2 DRD5 DRD3 DRD2
3 integral component of plasma membrane GO:0005887 9.81 SLC6A4 SLC6A3 HTR1B GABRA2 DRD5 DRD4
4 axon GO:0030424 9.8 SLC6A3 GABRA2 DRD2 COMT BDNF
5 GABA-ergic synapse GO:0098982 9.61 GABRA2 DRD3 DRD2
6 integral component of postsynaptic membrane GO:0099055 9.54 SLC6A4 SLC6A3 DRD2
7 dopaminergic synapse GO:0098691 9.46 SLC6A3 DRD2
8 serotonergic synapse GO:0099154 9.26 SLC6A4 HTR1B
9 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 HTR1B DRD2
10 dendrite GO:0030425 9.17 HTR1B GABRA2 DRD4 DRD2 CYBB COMT

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 PRL HTR1B GABRA2 DRD5 DRD4 DRD3
2 response to ethanol GO:0045471 9.93 SLC6A3 HTR1B DRD3 DRD2
3 chemical synaptic transmission GO:0007268 9.93 NPY HTR1B GABRA2 DRD5 DRD4 DBH
4 cellular calcium ion homeostasis GO:0006874 9.91 DRD5 DRD4 DRD3 DRD2
5 response to nutrient GO:0007584 9.88 SLC6A4 CYBB BCHE
6 memory GO:0007613 9.88 SLC6A4 DBH BDNF
7 locomotory behavior GO:0007626 9.88 SLC6A3 DRD3 DRD2 DBH
8 response to drug GO:0042493 9.87 SLC6A4 SLC6A3 DRD3 DRD2 CYBB COMT
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.86 NPY HTR1B DRD4
10 learning GO:0007612 9.86 DRD3 COMT BCHE
11 social behavior GO:0035176 9.84 SLC6A4 DRD4 DRD3
12 neurotransmitter transport GO:0006836 9.84 SLC6A4 SLC6A3 GABRA2
13 visual learning GO:0008542 9.83 DRD3 DRD2 DBH
14 feeding behavior GO:0007631 9.81 NPY HTR1B DRD2
15 associative learning GO:0008306 9.8 DRD5 DRD2 DBH
16 regulation of dopamine secretion GO:0014059 9.79 HTR1B DRD3 DRD2
17 negative regulation of blood pressure GO:0045776 9.78 DRD5 DRD3 DRD2
18 arachidonic acid secretion GO:0050482 9.77 DRD4 DRD3 DRD2
19 negative regulation of protein secretion GO:0050709 9.77 DRD4 DRD3 DRD2
20 dopamine receptor signaling pathway GO:0007212 9.76 DRD5 DRD4 DRD2
21 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.74 DRD5 DRD3 DRD2
22 response to pain GO:0048265 9.73 DBH COMT
23 behavioral response to cocaine GO:0048148 9.73 DRD4 DRD3 DRD2
24 response to amphetamine GO:0001975 9.73 DRD5 DRD4 DRD2 DBH
25 vasoconstriction GO:0042310 9.72 SLC6A4 HTR1B
26 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
27 negative regulation of cytosolic calcium ion concentration GO:0051481 9.72 DRD3 DRD2
28 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 SLC6A3
29 G protein-coupled receptor internalization GO:0002031 9.72 HTR1B DRD3 DRD2
30 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
31 catecholamine metabolic process GO:0006584 9.71 MAOA COMT
32 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.71 DRD4 DRD3
33 neurotransmitter catabolic process GO:0042135 9.71 MAOA COMT
34 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD3 DRD2
35 negative regulation of synaptic transmission GO:0050805 9.7 DRD2 BCHE
36 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.7 DRD5 DRD3
37 regulation of dopamine metabolic process GO:0042053 9.7 SLC6A3 DRD4
38 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD4 DRD3 DRD2
39 monoamine transport GO:0015844 9.69 SLC6A4 SLC6A3
40 adenohypophysis development GO:0021984 9.69 SLC6A3 DRD2
41 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 HTR1B DRD3 DRD2
42 hyaloid vascular plexus regression GO:1990384 9.68 SLC6A3 DRD2
43 heterocycle metabolic process GO:0046483 9.68 CYP2D6 CYP2C19
44 drinking behavior GO:0042756 9.68 HTR1B DRD2
45 regulation of potassium ion transport GO:0043266 9.67 DRD3 DRD2
46 monoterpenoid metabolic process GO:0016098 9.67 CYP2D6 CYP2C19
47 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.67 DRD5 DRD3 DRD2
48 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.66 DRD3 DRD2
49 fear response GO:0042596 9.65 DRD4 DBH
50 regulation of locomotion involved in locomotory behavior GO:0090325 9.65 DRD3 DRD2

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 MAOA DBH CYP2D6 CYP2C19 CYBB
2 G protein-coupled receptor activity GO:0004930 9.8 NPY HTR1B DRD5 DRD4 DRD3 DRD2
3 monooxygenase activity GO:0004497 9.61 DBH CYP2D6 CYP2C19
4 neurotransmitter receptor activity GO:0030594 9.54 HTR1B GABRA2 DRD4
5 neurotransmitter transporter activity GO:0005326 9.48 SLC6A4 SLC6A3
6 serotonin binding GO:0051378 9.4 SLC6A4 HTR1B
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
8 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A4 SLC6A3
9 dopamine binding GO:0035240 9.26 SLC6A3 DRD5 DRD4 DRD2
10 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD5 DRD4 DRD3 DRD2
Sources

Sources for Substance Abuse

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....